A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C.
about
Impact of new treatment options for hepatitis C virus infection in liver transplantationHepatitis C in human immunodeficiency virus co-infected individuals: Is this still a "special population"?Liver resection and transplantation in hepatocellular carcinomaA Lead-In with Silibinin Prior to Triple-Therapy Translates into Favorable Treatment Outcomes in Difficult-To-Treat HIV/Hepatitis C Coinfected PatientsTelaprevir- and boceprevir-based tritherapies in real practice for F3-F4 pretreated hepatitis C virus patients.Efficacy and safety of faldaprevir, deleobuvir, and ribavirin in treatment-naive patients with chronic hepatitis C virus infection and advanced liver fibrosis or cirrhosis.Treatment of hepatitis C virus infection in patients with cirrhosis and predictive value of model for end-stage liver disease: Analysis of data from the Hepa-C registry.Economic assessment of eltrombopag in the treatment of thrombocytopenia.Effectiveness and safety of first-generation protease inhibitors in clinical practice: Hepatitis C virus patients with advanced fibrosisHepatitis C Point-of-Care Screening in Retail Pharmacies in the United StatesProcesses to manage analyses and publications in a phase III multicenter randomized clinical trialCost analysis of sofosbuvir/ribavirin versus sofosbuvir/simeprevir for genotype 1 hepatitis C virus in interferon-ineligible/intolerant individuals.Systematic review: identifying patients with chronic hepatitis C in need of early treatment and intensive monitoring--predictors and predictive models of disease progressionNonresponse to interferon-α based treatment for chronic hepatitis C infection is associated with increased hazard of cirrhosis.Arterial blood pressure is closely related to ascites development in compensated HCV-related cirrhosisBoceprevir for chronic HCV genotype 1 infection in treatment-experienced patients with severe fibrosis or cirrhosis: The Greek real-life experience.Cost-effectiveness and population outcomes of general population screening for hepatitis C.Estimating cost-effectiveness associated with all-oral regimen for chronic hepatitis C in China.Cost-effectiveness of new antiviral regimens for treatment-naïve U.S. veterans with hepatitis C.Association of γ-glutamyl transferase (GGT) activity with treatment and clinical outcomes in chronic hepatitis C (HCV).Economic and Public Health Impacts of Policies Restricting Access to Hepatitis C Treatment for Medicaid Patients.A Cost-Utility Analysis of Different Antiviral Medicine Regimens in Patients With Chronic Hepatitis C Virus Genotype 1 Infection.Chronic hepatitis C genotype 1 virus: who should wait for treatment?HCC: current surgical treatment concepts.Hepatitis C-A clinical review.Potential market size and impact of hepatitis C treatment in low- and middle-income countries.Assessment of cost of innovation versus the value of health gains associated with treatment of chronic hepatitis C in the United States: The quality-adjusted cost of care.Management of Advanced Fibrosis in the Context of Hepatitis C Virus Infection.The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe.Sofosbuvir and simeprevir without ribavirin effectively treat hepatitis C virus genotype 1 infection after liver transplantation in a two-center experience.Usefulness of MR elastography for detecting clinical progression of cirrhosis from child-pugh class A to B in patients with type C viral hepatitis.Sofosbuvir/Velpatasvir in Patients With Hepatitis C Virus Genotypes 1-6 and Compensated Cirrhosis or Advanced Fibrosis.Modelling cost-effectiveness and health gains of a "universal" vs. "prioritized" HCV treatment policy in a real-life cohort.Hepatitis C direct antiviral drugs and hepatic decompensation in patients with advanced cirrhosis: culprit or innocent bystander?The CUPIC algorithm: an accurate model for the prediction of sustained viral response under telaprevir or boceprevir triple therapy in cirrhotic patients.The natural history of HCV-related cirrhosis and its temporal progression across the different clinical stages.Future complications of chronic hepatitis C in a low-risk area: projections from the hepatitis c study in Northern Norway.Role of systemic inflammation in cirrhosis: From pathogenesis to prognosis.Prospective cohort study on the outcomes of hepatitis C virus-related cirrhosis in South Korea.Efficacy of lead-in silibinin and subsequent triple therapy in difficult-to-treat HIV/hepatitis C virus-coinfected patients.
P2860
Q26782017-1133D69E-48FE-4E5E-AF53-BB6E4FD41308Q26798469-9BB8E2B7-3517-475E-9FBA-49DD74E556FAQ26823395-A37A77F6-76EF-40FF-8A95-10B9A925DE16Q28546535-B6481991-763F-4DCA-B907-4408ECE60777Q30430083-DBC36422-7120-41AE-896A-A146649D0C8FQ30620900-A63256C2-C9D4-4C70-A4F9-889D441D85FDQ31160142-4EC31CF2-3F15-49D6-902C-C0E484761544Q33424436-F72FAB3F-E92A-4554-9A46-BD175FA7AA81Q33425278-6E3F3A84-2491-49A5-99AA-68E6F69CD5BCQ33595820-827397B1-B906-4132-BCB4-76A8CCFBDF27Q33694159-1DE9AE21-EDFA-4E28-A2C4-CDD0FD2ED5F2Q33831652-1929CCFA-6091-413C-9443-F25B48EA4129Q34207037-6E818F43-3743-47E7-803D-F395014E87FBQ34700417-FA8C0E60-8491-435F-80A3-DE96ADA008E2Q35155028-B144BB0A-421C-4466-A9E6-3D86E7629CACQ36098496-E4AA3BA6-B6BA-42E8-B726-0919DDEF3A08Q36115516-E1C5241C-FCB6-4DF8-AAD8-6F2C8F0B603CQ36336005-6B81DD22-6FC7-47C3-B701-F5A9443C7598Q36479439-B9041B18-05C9-4153-9A2F-C6CAA2329618Q36759370-0258F4F7-D4AF-4F46-9176-FB8B0D4D183DQ37027342-4B704CFA-B997-419E-84B4-56230CEFD928Q37629097-7C232F02-D6F5-4AC6-8875-C30119EF360EQ37654449-A3300F23-4BFC-471C-B65E-2A3AA620822EQ37980015-CBFC3776-EAA8-42D1-9981-70ED98EC7F86Q38812892-634C46D5-3EDA-4274-984F-9169DFAE2FE8Q38902281-748E0DD2-AD54-43AB-9425-FE535F0B6F78Q38980602-CBDBBAB0-0F93-492E-B12E-16E67647715BQ39237709-A93EA08C-C245-43A6-A451-B91921E028C3Q39471203-F7239C5E-7C50-48CD-8D32-25442B71E4BEQ39885523-25F9B161-50C4-42EE-90E1-3BA662E445E7Q39957915-CABA90B7-7157-4F66-B213-55CA838C70DAQ40102621-E0DB71F0-3F8E-4C14-B450-3FE3773939F6Q40121053-DADAACAF-9B9D-4B4C-A62C-B59C86D3E4B6Q40364506-0D042B3C-C70D-40B0-9EE1-140A9CABDBA4Q41542394-EC955AC2-49FC-46F7-9F8D-8E47CCCF4906Q41556762-210D0611-A16D-4864-8935-D4092C0B369FQ41711879-6B1D559D-F6D1-48B5-8F96-79955CD2AFA4Q42042373-14461486-2F2A-4829-8453-3574E397A358Q42154497-6675F2B3-0C2E-43F4-91D6-DD69A549F292Q42212364-FBBE0D82-39E7-4BC0-99FA-CA387AD37234
P2860
A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
A prospective study of the rat ...... advanced chronic hepatitis C.
@ast
A prospective study of the rat ...... advanced chronic hepatitis C.
@en
type
label
A prospective study of the rat ...... advanced chronic hepatitis C.
@ast
A prospective study of the rat ...... advanced chronic hepatitis C.
@en
prefLabel
A prospective study of the rat ...... advanced chronic hepatitis C.
@ast
A prospective study of the rat ...... advanced chronic hepatitis C.
@en
P2093
P2860
P356
P1433
P1476
A prospective study of the rat ...... y advanced chronic hepatitis C
@en
P2093
Anna S Lok
Anne M Stoddard
Chihiro Morishima
Elizabeth C Wright
Gregory T Everson
Gyongyi Szabo
HALT-C Trial Group
Hae-Young Kim
Herbert L Bonkovsky
James E Everhart
P2860
P304
P356
10.1002/HEP.24370
P407
P577
2011-06-23T00:00:00Z